{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:50:15Z","timestamp":1788814215996,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.cld.2023.05.008","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T16:01:31Z","timestamp":1688745691000},"page":"937-954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["State of the Art"],"prefix":"10.1016","volume":"27","author":[{"given":"Emuejevuoke","family":"Umukoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Alukal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Pak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2023.05.008_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.13777","article-title":"Hepatitis delta virus: disease assessment and stratification","author":"Koffas","year":"2023","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2023.05.008_bib2","volume":"vol. 2","author":"Jameson","year":"2018"},{"issue":"3","key":"10.1016\/j.cld.2023.05.008_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2023.05.008_bib4","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"Urban","year":"2021","journal-title":"Gut"},{"issue":"18","key":"10.1016\/j.cld.2023.05.008_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810817","article-title":"Medical advances in hepatitis D therapy: molecular targets","volume":"23","author":"Vogt","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.cld.2023.05.008_bib6","doi-asserted-by":"crossref","first-page":"a021550","DOI":"10.1101\/cshperspect.a021550","article-title":"Hepatitis D virus coinfection and superinfection","volume":"4","author":"Negro","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"10.1016\/j.cld.2023.05.008_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1055\/s-0032-1323628","article-title":"Clinical features of hepatitis D","volume":"32","author":"Farci","year":"2012","journal-title":"Semin Liver Dis"},{"issue":"4","key":"10.1016\/j.cld.2023.05.008_bib8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1034\/j.1600-0676.2001.021004254.x","article-title":"Clearance of hepatitis B surface antigen in chronic carriers of hepatitis delta antibodies","volume":"21","author":"Niro","year":"2001","journal-title":"Liver"},{"issue":"9785","key":"10.1016\/j.cld.2023.05.008_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","article-title":"Hepatitis delta virus","volume":"378","author":"Hughes","year":"2011","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.cld.2023.05.008_bib10","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.3748\/wjg.v25.i32.4580","article-title":"Chronic hepatitis delta: a state-of-the-art review and new therapies","volume":"25","author":"Gilman","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2023.05.008_bib11","doi-asserted-by":"crossref","first-page":"652962","DOI":"10.3389\/fmicb.2021.652962","article-title":"Hepatitis delta virus (HDV) and delta-like agents: insights into their origin","volume":"12","author":"Netter","year":"2021","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.cld.2023.05.008_bib12","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/jvi.67.1.366-372.1993","article-title":"Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion","volume":"67","author":"Sureau","year":"1993","journal-title":"J\u00a0Virol"},{"issue":"6088","key":"10.1016\/j.cld.2023.05.008_bib13","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/323508a0","article-title":"Structure, sequence and expression of the hepatitis delta (delta) viral genome","volume":"323","author":"Wang","year":"1986","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.cld.2023.05.008_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/v12050538","article-title":"HDVdb: a comprehensive hepatitis D virus database","volume":"12","author":"Usman","year":"2020","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.cld.2023.05.008_bib15","doi-asserted-by":"crossref","first-page":"666","DOI":"10.4254\/wjh.v5.i12.666","article-title":"Life cycle and pathogenesis of hepatitis D virus: a review","volume":"5","author":"Abbas","year":"2013","journal-title":"World J Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2023.05.008_bib16","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1128\/JVI.76.8.3920-3927.2002","article-title":"Rolling circle replication of hepatitis delta virus RNA is carried out by two different cellular RNA polymerases","volume":"76","author":"Macnaughton","year":"2002","journal-title":"J\u00a0Virol"},{"issue":"1","key":"10.1016\/j.cld.2023.05.008_bib17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/v2010189","article-title":"Interaction of host cellular proteins with components of the hepatitis delta virus","volume":"2","author":"Greco-Stewart","year":"2010","journal-title":"Viruses"},{"issue":"5061","key":"10.1016\/j.cld.2023.05.008_bib18","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.1598578","article-title":"Identification of a prenylation site in delta virus large antigen","volume":"256","author":"Glenn","year":"1992","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.cld.2023.05.008_bib19","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1128\/jvi.67.12.7659-7662.1993","article-title":"Isoprenylation mediates direct protein-protein interactions between hepatitis large delta antigen and hepatitis B virus surface antigen","volume":"67","author":"Hwang","year":"1993","journal-title":"J\u00a0Virol"},{"issue":"4","key":"10.1016\/j.cld.2023.05.008_bib20","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/hep.31214","article-title":"Long-term study of hepatitis delta virus infection at secondary care centers: the impact of viremia on liver-related outcomes","volume":"72","author":"Kamal","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2023.05.008_bib21","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cgh.2013.01.025","article-title":"Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia","volume":"11","author":"Brichler","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2023.05.008_bib22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2023.05.008_bib23","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1086\/382133","article-title":"Quantitation of the level of hepatitis delta virus RNA in serum, by real-time polymerase chain reaction--and its possible correlation with the clinical stage of liver disease","volume":"189","author":"Yamashiro","year":"2004","journal-title":"J\u00a0Infect Dis"},{"issue":"5","key":"10.1016\/j.cld.2023.05.008_bib24","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1128\/JCM.43.5.2363-2369.2005","article-title":"Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients","volume":"43","author":"Le Gal","year":"2005","journal-title":"J\u00a0Clin Microbiol"},{"issue":"6","key":"10.1016\/j.cld.2023.05.008_bib25","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1128\/JCM.00084-10","article-title":"Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics","volume":"48","author":"Mederacke","year":"2010","journal-title":"J\u00a0Clin Microbiol"},{"issue":"5","key":"10.1016\/j.cld.2023.05.008_bib26","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jhep.2009.10.036","article-title":"Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D","volume":"52","author":"Schaper","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2023.05.008_bib27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1128\/JCM.02027-16","article-title":"Performance characteristics of a new consensus commercial kit for hepatitis D virus RNA viral load quantification","volume":"55","author":"Le Gal","year":"2017","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cld.2023.05.008_bib28","unstructured":"Jena A, Konrad-Zuse-Strasse AG, Hofmann U, et al. Improved Management of Hepatitis D: Standardized Quantification of HDV RNA Publication Monitoring of HDV RNA Improved Management of Hepatitis D: Standardized Quantification of HDV RNA. Available at: www.analytik-jena.com. Accessed March 3, 2023."},{"issue":"4","key":"10.1016\/j.cld.2023.05.008_bib29","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/biomedicines10040792","article-title":"Clinical application of droplet digital PCR for hepatitis delta virus quantification","volume":"10","author":"Olivero","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.cld.2023.05.008_bib30","doi-asserted-by":"crossref","first-page":"100356","DOI":"10.1016\/j.jhepr.2021.100356","article-title":"Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system","volume":"3","author":"Pfl\u00fcger","year":"2021","journal-title":"JHEP Reports"},{"key":"10.1016\/j.cld.2023.05.008_bib31","unstructured":"Chudy M, Hanschmann KM, Bozdayi M, et al. EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 21 to 25 October 2013 Collaborative Study to Establish a World Health Organization International Standard for Hepatitis D Virus RNA for Nucleic Acid Amplification Technique (NAT)-Based Assays.; 2013. Available at: http:\/\/www.who.int\/about\/licensing\/copyright_form\/en\/index.html Accessed March 3, 2023."},{"issue":"5","key":"10.1016\/j.cld.2023.05.008_bib32","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/hep.28772","article-title":"First international external quality assessment for hepatitis delta virus RNA quantification in plasma","volume":"64","author":"le Gal","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2023.05.008_bib33","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1128\/JVI.78.5.2537-2544.2004","article-title":"Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades","volume":"78","author":"Radjef","year":"2004","journal-title":"J\u00a0Virol"},{"issue":"6","key":"10.1016\/j.cld.2023.05.008_bib34","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1053\/j.gastro.2006.01.035","article-title":"Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients","volume":"130","author":"Su","year":"2006","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2023.05.008_bib35","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jhep.2020.06.038","article-title":"Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta","volume":"73","author":"Roulot","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2023.05.008_bib36","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrgastro.2016.126","article-title":"Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options","volume":"13","author":"Lempp","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2023.05.008_bib37","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jhep.2019.12.028","article-title":"Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1","volume":"72","author":"Spaan","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2023.05.008_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"10","key":"10.1016\/j.cld.2023.05.008_bib39","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3390\/v13101912","article-title":"Hepatitis D review: challenges for the resource-poor setting","volume":"13","author":"Lee","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.cld.2023.05.008_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cld.728","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"12","author":"Terrault","year":"2018","journal-title":"Clin Liver Dis"},{"issue":"10","key":"10.1016\/j.cld.2023.05.008_bib41","doi-asserted-by":"crossref","first-page":"100547","DOI":"10.1016\/j.jhepr.2022.100547","article-title":"Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D","volume":"4","author":"Palom","year":"2022","journal-title":"JHEP Reports"},{"key":"10.1016\/j.cld.2023.05.008_bib42","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.virusres.2018.03.013","article-title":"Hepatitis D diagnostics:Utilization and testing in the United States","volume":"250","author":"Safaie","year":"2018","journal-title":"Virus Res"},{"issue":"28","key":"10.1016\/j.cld.2023.05.008_bib43","doi-asserted-by":"crossref","first-page":"773","DOI":"10.15585\/mmwr.mm6728a2","article-title":"Access to treatment for hepatitis B virus infection \u2014 worldwide, 2016","volume":"67","author":"Hutin","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"10.1016\/j.cld.2023.05.008_bib44","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/ajg.2009.248","article-title":"Histological disease in asian-Americans with chronic hepatitis B, high hepatitis B virus DNA and normal alanine aminotransferase levels","volume":"104","author":"Nguyen","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2023.05.008_bib45","doi-asserted-by":"crossref","first-page":"12031","DOI":"10.1038\/s41598-018-30229-8","article-title":"Early-onset liver cancer in South America associates with low hepatitis B virus DNA burden","volume":"8","author":"Marchio","year":"2018","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.cld.2023.05.008_bib46","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.cgh.2020.04.091","article-title":"Should treatment indications for chronic hepatitis B Be expanded?","volume":"19","author":"Jeng","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2023.05.008_bib47","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41575-020-00398-x","article-title":"Extending treatment eligibility for chronic hepatitis B virus infection","volume":"18","author":"McNaughton","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2023.05.008_bib48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cld.2022.08.001","article-title":"Chronic hepatitis B virus and hepatitis D virus","volume":"27","author":"Robinson","year":"2023","journal-title":"Clin Liver Dis"},{"issue":"4","key":"10.1016\/j.cld.2023.05.008_bib49","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.cld.2023.05.008_bib50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2023.05.008_bib51","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2018.12.022","article-title":"Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy","volume":"70","author":"Yurdaydin","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2023.05.008_bib52","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.cld.2023.05.008_bib53","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1002\/hep.32082","article-title":"Endpoints and new options for treatment of chronic hepatitis D","volume":"74","author":"Lok","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.008_bib54","article-title":"Treatment endpoints for chronic hepatitis D","author":"Metin","year":"2022","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.cld.2023.05.008_bib55","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/apt.13734","article-title":"HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response","volume":"44","author":"Niro","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.cld.2023.05.008_bib56","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2023.05.008_bib57","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep4.1633","article-title":"Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139-Ca and pegylated interferon therapy in chronic hepatitis B virus\/hepatitis delta virus coinfection","volume":"5","author":"Bazinet","year":"2021","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.cld.2023.05.008_bib58","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/hep4.1821","article-title":"HBcrAg levels are associated with virological response to treatment with interferon in patients with hepatitis delta","volume":"6","author":"Sandmann","year":"2022","journal-title":"Hepatol Commun"},{"issue":"9","key":"10.1016\/j.cld.2023.05.008_bib59","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1478-3231.2012.02831.x","article-title":"HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome","volume":"32","author":"Heidrich","year":"2012","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.cld.2023.05.008_bib60","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.3390\/v13122371","article-title":"A\u00a0rapid point-of-care test for the serodiagnosis of hepatitis delta virus infection","volume":"13","author":"Lempp","year":"2021","journal-title":"Viruses"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:00:24Z","timestamp":1761069624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326123000685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1089326123000685"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2023.05.008","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State of the Art","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2023.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}